Clinical Trial Update: A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. [Phase 2]

View source ↗

Summary

Phase 2 study evaluating rituximab (MabThera) in patients with immune thrombocytopenia has completed enrollment, with results posted in February 2015. The trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• MabThera (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Idiopathic Thrombocytopenic Purpura | Phase 2 | Status: COMPLETED | Results posted: 2015-02-23